Alcinous Pharmaceuticals strive to design and develop therapeutics for aggressive cancers. Founded in 2016 by three PhD students at the University of Rhode Island, Alcinous Pharmaceuticals uses a novel drug discovery pipeline in tandem with their innovative team to develop new classes of therapeutics.
They design and develop new molecules that modulate the activity of well-established protein targets related to oncology and other pathologies. Their computational and synthetic approaches facilitate the identification and development of novel target ligands and new therapeutics.